A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants with Parkinson's Disease
Latest Information Update: 15 Jun 2025
At a glance
- Drugs TB 006 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors TrueBinding
Most Recent Events
- 20 Feb 2025 Status changed from not yet recruiting to recruiting.
- 14 Jan 2025 Status changed from planning to not yet recruiting.
- 22 Nov 2024 New trial record